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To map the regions of the external envelope glycoproteins of human immunodeficiency virus type 1 (HIV-1)
involved in the process of membrane fusion, we determined the syncytium-inducing capacity of a panel of
transiently expressed chimeric envelope genes. This panel was generated by exchanging gene fragments
between four previously studied envelope genes that exhibited a high degree of sequence homology yet displayed
marked differences in syncytium-inducing capacity when expressed by recombinant vaccinia virus. The results
demonstrate that multiple regions of the HIV-1 envelope glycoproteins are involved in syncytium formation.
Some fragments, most notably those containing the V2 or V3 region, can transfer syncytium-inducing capacity
to envelope proteins previously not capable of inducing syncytia. Moreover, it is shown that such regions
functionally interact with other envelope regions, especially one encompassing the V4 and V5 regions of gpl20
or a region encompassing part of gp4l, to exert their function in membrane fusion.
Human immunodeficiency virus type 1 (HIV-1) enters the
cell through a multistep process. Binding of the viral external
glycoprotein gpl20 to the cellular receptor CD4 ultimately
results in fusion of the viral envelope and the cellular
membrane (6, 22). A similar fusion process between HIV-1-
infected cells expressing viral envelope glycoproteins and
(uninfected) cells expressing CD4 may lead to the formation
of syncytia (23, 29).
HIV-1 isolates differ in their capacity to induce syncytia in
vitro. On the basis of both this capacity and other in vitro
biological properties, such as replication rate and cytotro-
pism, syncytium-inducing (SI) and non-SI (NSI) HIV-1
isolates are distinguished (35). These two categories largely
overlap with the "rapid-high" and "slow-low" viruses,
respectively, described by others (10). The isolation of
HIV-1 variants with an SI phenotype correlates with the
subsequent rapid decline of CD4+ cell numbers and progres-
sion to AIDS (4, 21, 36), which suggests that the emergence
of viruses with a cytopathic SI phenotype plays a role in the
pathogenesis of AIDS. Dissection of the process of mem-
brane fusion that leads to syncytium formation may contrib-
ute to our understanding of its role in HIV-1 biology and
pathogenesis.
HIV-1 envelope glycoproteins contain all of the viral
information required for syncytium formation (22, 34), and
several of the determinants that mediate the underlying
membrane fusion process have been identified. Genetic
variation in such determinants could theoretically result in
differences in SI capacity between different HIV-1 envelope
genes. For efficient binding to the cellular receptor CD4, an
intact CD4-binding region is needed. Amino acid residues
involved in CD4 binding are scattered among at least four
different regions of gpl20 (26). The potential effects of
variation in these regions on syncytium formation has not
yet been studied in detail. Syncytium formation by both
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simian immunodeficiency virus and HIV-1 envelope genes
could be experimentally manipulated by introducing muta-
tions in the fusion domain at the amino terminus of the
transmembrane glycoprotein gp4l (2, 12). Although natural
sequence variation in the fusion domain of SI and NSI
isolates was also found, such variation does not contribute
significantly to the differences in syncytium formation (1).
Naturally occurring sequence variation in the V3 loop,
however, does seem to be relevant for the differences in the
capacities of HIV-1 isolates to induce syncytia. Site-directed
mutagenesis experiments have demonstrated a direct role for
this region in HIV-1-induced membrane fusion (13, 27), and
genetic exchange experiments between molecular clones of
HIV-1 with different SI capacities have shown that such
differences may map to the V3 region (5, 8). This same
region also contains determinants that control HIV-1 cell
tropism (20). Taken together, these data suggest a pivotal
role for the V3 region of HIV-1 envelope.
Neutralizing antibodies directed against both the CD4-
binding region and the V3 region have been described
previously (16, 17, 28, 30, 32, 37). Such antibodies exert their
function upon binding to their target sites either by inhibition
of CD4 binding or through interference with an essential step
in the process that leads from CD4 binding to fusion.
Neutralizing antibodies that are directed against envelope
regions for which no function in the membrane fusion
process is known (e.g., the V2 region [14] or the central
region of gp4l [7]) have also been described. These data and
the results of studies employing site-directed mutagenesis
(19, 38) suggest that other regions than those described
above may be involved in the membrane fusion process.
Nevertheless, in studies in which gene fragments are ex-
changed between pairs of molecular clones with different SI
capacities, the determinants involved are repeatedly mapped
to an envelope gene fragment that always includes the V3
region that has already been identified (5, 8). In an attempt to
screen for additional membrane fusion-mediating determi-
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FIG. 1. Positions of the generated gene fragments relative to the
complete envelope gene (top bar). The hypervariable regions Vi to
V5, fusion domain (FD), cleavage site (arrow), and the restriction
enzymes used are shown. The gene fragments are named after the
flanking restriction sites.
nants, we performed the mapping experiments described in
this report.
The starting material for this study consisted of four
complete HIV-1 envelope genes described elsewhere (1).
Since these envelope genes were obtained from one patient
at a single time point, these genes are highly related geneti-
cally, yet they display heterogeneous SI capacities: two
induce syncytia in peripheral blood mononuclear cells and in
SUP-Ti cells, whereas the two others do not. We have
generated 40 chimeric envelope genes, mainly between SI
and NSI envelope genes, and tested these genes in a syncy-
tium-forming assay. Our results demonstrate that multiple
regions of the HIV-1 envelope glycoproteins control SI
capacity; most notably, those regions that contain the V2 or
V3 region can transfer SI capacity to envelope proteins
previously not capable of inducing syncytia. Moreover, our
data show that the capacity of the V2 and V3 regions to
mediate syncytium formation also depends on additional
envelope regions encompassing the V4 and V5 regions of
gpl20 or a region encompassing part of gp4l.
MATERIALS AND METHODS
Construction of chimeric envelope genes. Four previously
characterized HIV-1 envelope genes from biological clones
obtained from patient 16 at a single time point and designated
16.1 to 16.4 (1) were used to generate a set of chimeric
envelope genes. These parental genes were originally cloned
in the pSCll vaccinia virus expression vector (3) and in the
plasmid pGEM7- (Promega). Chimeric envelope genes were
constructed by exchanging gene fragments generated with
restriction enzymes (NdeI, Spel, StuI, HindII, CvnI, and
AvrII) with conserved restriction sites in all four envelope
genes and the restriction enzymes XhoI and XmaI, which
provide convenient sites in the cloning vectors, as depicted
in Fig. 1. The resulting envelope chimeras are designated
according to the exchanged gene fragment and the two
parental envelope genes (see Fig. 3). All chimeric envelope
genes were tested by restriction mapping using restriction
sites that were not conserved in the original four envelope
genes. Occasionally, chimeric envelope genes were partially
sequenced to verify the cloning procedure.
Cloning of chimeric envelope genes in transient expression
vector. The chimeric envelope genes were cloned in the
simian virus 40-based expression plasmid pSRHS (a gener-
ous gift of Eric Hunter, University of Alabama at Birming-
ham, Birmingham [9]). The HIV env gene sequences were
cloned by exchanging the original env gene of HXB2 with
KpnI and SmaI restriction enzymes (Fig. 1). All the ex-
pressed chimeric envelope genes thus contain the signal
peptide and the first 13 amino acids of the HXB2 envelope
protein.
DNA transfection and syncytium formation assay. All gen-
erated constructs were transfected in CEMx174 cells (31) by
electroporation. Five million cells were mixed with 20 ,ug of
DNA in 250 ,ul of RPMI medium (GIBCO) supplemented
with 10% fetal calf serum (FCS) in a 4-mm-wide electropo-
ration cuvette (Eurogentec S.A.). After electroporation (200
V, 960 p,F; Bio-Rad gene pulser), the cells were kept on ice
for 10 min and then transferred to small culture flasks
containing 10 ml of RPMI medium. Forty-eight hours after
electroporation, viable cells were isolated on a Ficoll density
gradient, and 2 x 105 of these cells were cocultured for 16 h
with an equal amount of SUP-Ti cells (33). Syncytia were
only found after cocultivation. The relative sizes and num-
bers of syncytia found in each culture were scored indepen-
dently by three researchers. The size of syncytia was quan-
tified as follows: small (+), up to five times the size of single
cells; large (+ + +), giant syncytia estimated to contain over
100 fused cells (scored as being larger than 250 ,um in
diameter), or intermediate (+ +). For examples of syncytium
size, see Fig. 2.
env expression. At the time that the cultures were scored
for syncytium formation, separately cultured portions of the
Ficoll-purified cells were treated as follows: (i) spotted onto
microscope slides and fixed with ice-cold ethanol (70%) for
immunofluorescence and stored at -20°C and (ii) lysed with
1% empigen BB (25) and frozen at -70°C for enzyme-linked
immunosorbent assay. Finally, a sample of the culture
supernatants was frozen and also tested in an ELISA.
(i) Immunofluorescence. The percentage of envelope pro-
tein-expressing cells was determined by an immunofluores-
cence assay. The fixed cells on microscope slides were
incubated with patient serum (1:70 dilution) and exposed to
fluorescein isothiocyanate (FITC)-conjugated sheep anti-
human immunoglobulin Gi. The percentages of positive
cells were scored with a fluorescence microscope.
(ii) gp120 ELISA. To determine the relative amounts of
envelope protein produced in the different transfected cell
cultures, a gpl20 ELISA that is based on an assay developed
by Moore et al. (24, 25) was used. Capture antibodies D7324
(Aalto BioReagents, Dublin, Ireland) were adsorbed on to
ELISA plates (Costar) by incubation overnight in 40 mM
NaHCO3, pH 9.6, at 4°C. D7324 is an affinity-purified
polyclonal sheep antiserum to the conserved carboxy-termi-
nal 15 amino acids of gpl20. The predicted amino acid
sequences of the four envelope genes used in this study are
completely homologous to this peptide (1). Unbound anti-
bodies were removed by washing each well four times with
200 p,l of the assay buffer (0.1 M NaCl, 0.1 M Tris, 0.1%
Tween 20, pH 7.5). All incubations were performed for 1 h at
37°C with assay buffer supplemented with 1% FCS and 0.5%
normal goat serum and terminated by washing each well four
times with 200 pul of assay buffer unless stated otherwise.
The wells were subsequently blocked with assay buffer
supplemented with serum. Next the wells were incubated
with 100-pul portions of a serial dilution of cell lysate or
culture supernatant for 2 h. Detection of the attached gpl20
was achieved by successive incubation of the wells with the
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FIG. 2. Syncytia induced upon cocultivation of transfected
CEMx174 cells with SUP-Ti cells. (A) No syncytia; intermediate-
size syncytia (B); and large syncytia (C).
following: a 1:2,000 dilution of patient serum, a 1:2,000
dilution of biotinylated goat antihuman IgG (Amersham),
and streptavidin-horseradish peroxidase conjugate (strept-
ABComplex/HRP [Dako A/S]). Finally, the plates were
incubated with tetramethylbenzidine-H202. The reaction
was stopped by adding 50 ,ul of 2 M H2SO4, and the optical
density at 450 nm was read with a Titertek Multiskan (Flow
Laboratories). All gpl20 ELISA values for the different
constructs were related to each other and expressed as a
percentage of the maximum value measured. The assay can
routinely detect 20 pg of recombinant gpl20 (Celltech,
provided to us through the Medical Research Council AIDS
reagent project).
(iii) CD4 ELISA. The CD4 ELISA used was very similar to
the gpl20 ELISA described above. The only difference was
that the envelope proteins are now captured to the solid
phase by binding to attached CD4. Recombinant soluble
CD4 (100 ng/well; American Bio-Technologies; provided to
us through the Medical Research Council AIDS reagent
project) was adsorbed on to ELISA plates (Costar) by
incubation overnight in phosphate-buffered saline (pH 7.2) at
4°C. All subsequent incubations were performed as de-
scribed for the gpl20 ELISA, except that the detecting
patient serum was diluted 1:3,000.
Nucleotide sequence accession numbers. The GenBank ac-
cession numbers for the envelope gene sequences derived
from biological clones 16.1 to 16.4 are L08655 to L08658,
respectively.
RESULTS
Construction of chimeric envelope genes. Chimeric enve-
lope genes were constructed from the four parental envelope
genes 16.1, 16.2, 16.3, and 16.4 described elsewhere (1). We
exchanged six different fragments between these four paren-
tal envelope genes to generate the 40 chimeric envelope
genes (Fig. 1 and 3). The chimeric envelope genes were
expressed in CEMx174 cells in transient expression experi-
ments.
Expression of gpl20. Expression of the envelope protein in
the transfected cells was monitored by ELISA and immuno-
fluorescence. In Table 1, the relative amount of gp120
produced (cell associated and shed in the culture medium) is
listed for each construct tested. The percentage of HIV-1
envelope protein-expressing cells in the population of trans-
fected CEMx174 cells varied from 0.6 to 4.6% of the total
(Table 1).
CD4 binding of expressed gpI20. By immunoprecipitation
we have previously shown that all four parental envelope
gene products were able to bind soluble CD4 (1). For the
present study, we also tested the expressed chimeric enve-
lope proteins for their ability to bind CD4. All chimeric
envelope proteins produced upon transfection of the gener-
ated constructs were able to bind CD4, as demonstrated by
the CD4-binding ELISA (results not shown). The exchange
of envelope gene fragments apparently did not interfere with
the CD4-binding abilities of these expressed gene products.
SI capacities of expressed envelope genes. In a previous
study (1), we have shown that upon expression in a recom-
binant vaccinia virus, the two parental SI envelope gene
products 16.1 and 16.2 induce syncytia in SUP-Ti cells,
whereas the NSI envelope gene products do not. For the
experiments described here, we therefore used SUP-Ti cells
as CD4-positive fusion partners. Upon transfection of
CEMx174 cells and subsequent cocultivation with SUP-Ti
cells, almost all expressed envelope chimeras gave rise to
the formation of syncytia. The sizes of the induced syncytia
differed substantially for the different constructs and were
highly reproducible. We have defined the SI capacity of the
chimeric envelope gene products as the maximum size of the
syncytia they induce in SUP-Ti cells. Within any range of
the quantitative parameters shown in Table 1, small and
large syncytia were observed. These results indicate that
syncytium size is a qualitative property of the (chimeric)
envelope and that the syncytium size is not dependent on
experimental variables that influence the amount of envelope
proteins produced at least not within the range observed in
these experiments.
Figure 3 shows the SI capacities of all generated chimeric
envelope constructs. The data presented are derived from
single representative experiments. Several control experi-
ments were performed, including multiple testing of the
J. VIROL.
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TABLE 1. Quantitative expression of gp120 by (chimeric)
envelope genes and sizes of the induced syncytia
mnv Syncytium
)dea sizeb
++
+++
+++
+++
+++
++
++
++
++
++
++
+
Envelope protein-
expressing cells
by IFA (%)C
2.6
1.9
3.8
2.7
NT
1.9
1.7
3.4
4.1
2.2
2.8
3.3
1.3
NT
2.0
0.6
1.0
4.6
2.9
1.6
2.3
1.8
1.8
2.7
gpl2O
ELISA (
4.2
0.9
3.7
3.2
1.8
1.2
1.5
NT
2.6
1.9
32NC ++ 3.3 26
24AX - 1.5 29
42AX +++ 1.8 45
32AX +++ 1.2 18
42HC +++ 1.8 42
42SSCX +++ 1.5 25
32HC +++ 3.3 50
24SA +++ 1.3 34
23SA +++ 4.6 31
32XS +++ 1.9 80
a Chimeric genes were named so that the name reflects construction of the
chimeric gene. ABCD is a chimeric envelope gene in which gene fragment CD
from parental env gene A is transferred to gene B. The envelope genes
obtained from biological clones 16.1 to 16.4 are referred to as 1 to 4.
b SI capacity of expressed envelope genes. Symbols: -, no syncytia; +,
small syncytia; + +, intermediate-size syncytia; +++, large syncytia.
c Percentage of envelope protein-expressing CEMx174 cells as monitored in
an immunofluorescence assay (IFA). NT, not tested.
d Relative amount of gpl20 produced by transfected CEMx174 cells (shed
in culture medium and cell associated) expressed as a percentage of the
maximum observed gpl20 expression.
same construct and complete reconstruction of some enve-
lope chimeras. In all of these cases, essentially similar
results were obtained.
Mapping of envelope determinants controlling SI capacity.
Figure 3A first shows the four parental envelope genes with
the sizes of the induced syncytia in SUP-Ti cells. As in our
experiments in which these same envelope genes were
expressed by recombinant vaccinia virus, only SI clone-
derived envelope gene products were capable of inducing
(large) syncytia (1). The same panel also lists seven chimeric
envelope constructs in which gene fragments between the
two SI clone-derived envelope genes (16.1 and 16.2) have
been exchanged. With the exception of construct 12XS that
induces intermediate-size syncytia, all constructs consisting
of solely SI clone-derived envelope gene sequences were
able to induce large syncytia.
For further analysis, we divided our constructs in two
subsets that each had sequences of one of the parental SI
envelope genes as a common denominator. Figure 3B and C
summarize the data for the subsets based on the SI genes
16.1 and 16.2, respectively, which were expected to yield
information on regions that positively influence syncytium
formation. Interestingly, dissimilar results were obtained for
both subsets.
Analysis of the constructs based on 16.1 sequences re-
vealed two small distinct regions containing determinants
that are important in syncytium formation. These regions are
the SS fragment located in the amino-terminal part of gpl20
(Fig. 3B, top) and the central HC fragment (Fig. 3B, center).
Both small fragments transfer considerable SI capacity from
the 16.1 SI envelope to both NSI envelope backgrounds. The
16.1 HC fragment alone transforms the NSI envelopes into
full SI envelopes upon expression. The 16.1 SS fragment (or
the larger XS fragment of 16.1) by itself transfers only the
capacity to form medium-size syncytia but in the presence of
other 16.1-derived fragments can transfer full SI capacity
(Fig. 3B, top).
Chimeric envelopes based on 16.2 sequences show also
that the same two distinct envelope regions are important in
syncytium formation. However, like the SS region of 16.1,
now both regions transfer full SI capacity only in the
presence of additional SI-derived sequences in the same
chimeric envelope construct (Fig. 3C).
DISCUSSION
We are studying the process of syncytium formation as a
model system to unravel the underlying mechanism of HIV-
1-induced membrane fusion. In the present study, we have
mapped the regions of the HIV-1 envelope proteins which
determine the SI capacity.
It has been demonstrated that syncytium formation is
mediated by the envelope glycoproteins of HIV-1, although
the exact mechanism has not been clarified (22, 34). In a
previous study (1), we provided evidence that differences in
the SI capacities of field isolates are dependent on differ-
ences in the envelope gene itself. To avoid possible interfer-
ence of long terminal repeat or regulatory gene functions
with envelope-induced syncytium formation, we have cho-
sen to analyze chimeric envelope genes that are transiently
expressed out of the context of the viral genome. The highly
homologous HIV-1 envelope genes that were obtained from
a single donor at the same time point and that were previ-
ously analyzed genetically and functionally served as the
basis for the experiments described here.
Since transient expression experiments lack internal con-
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trols for protein expression and function, we first studied the
levels of envelope protein production and the CD4-binding
capacity. For each transfection, experimental variables,
such as the percentage of gpl20-producing cells, the relative
amount of gpl20 produced, the number of syncytia, and the
CD4-binding capacity of the expressed recombinant protein,
were monitored. Within any range of the quantitative param-
eters, small and large syncytia were observed, which ex-
cluded the possibility that envelope protein expression was a
limiting factor in our experiments. This notion was sup-
ported by the observation that none of the quantitative
parameters correlated with the readouts of the experiments;
the size of the induced syncytia appears to be a genetic trait
of each individual construct. Finally, all expressed (chimer-
ic) envelope proteins were able to bind CD4.
In our approach, we have transferred fragments of SI
envelope genes to NSI envelope genes searching for regions
that positively influence the SI capacity. All of these con-
structs therefore contain genetic information from both SI
and NSI envelope genes. We found no evidence for NSI
clone-derived envelope regions that negatively influence the
SI capacity, but we were able to identify regions from SI
genes that transfer SI capacity to NSI backgrounds. The
mapping experiments show that multiple determinants lo-
cated on several envelope gene fragments contribute to
syncytium formation. In our opinion, the effects described
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FIG. 4. Predicted amino acid sequences of the hypervariable region V2 together with the predicted secondary structures and charge
differences. Amino acids identical to those of the consensus sequence (.) and deletions (-) are indicated. The predicted secondary structures
of the SI and NSI gene products are also given, at the top and bottom of the figure. The corresponding amino acid is predicted to be in the
following configurations; helical (H), extended stretch (E), turn (T) and coil (C). The underlined regions are predicted to have significantly
different secondary structures for the SI and NSI clone-derived V2 amino acid sequences. The charges are given in boldface type.
here are the results of multiple functional interactions be-
tween different regions of the envelope glycoproteins, we
distinguish SI regions (SIRs), regions which are by them-
selves capable of transferring considerable SI capacity, and
enhancing regions that enhance the SI capacity of SIRs but
by themselves are not or hardly capable to induce syncytia.
Both the SS and HC gene fragments of the 16.1 and 16.2 SI
envelopes can independently transfer considerable SI capac-
ity to an NSI envelope which identifies these regions as
SIRs. The 16.1 HC fragment alone is sufficient to transfer full
SI capacity. This SIR apparently functions independently of
the background sequence into which it is cloned. For the
other identified SIRs (the 16.2 HC fragment and the SS
fragment of 16.1 and 16.2) function is context dependent:
their SI capacity can be increased by the simultaneous
transfer of an enhancing region. An alternative explanation
for the described enhancements of syncytium formation by
enhancing regions could be a purely additive effect, since the
enhancing regions by themselves can also transfer some SI
capacity to NSI gene products. However, such additive
effects are not seen when two SIRs, e.g., the V2 and V3
regions of 16.2, are combined in one construct in the absence
of an enhancing region (construct 23NC [Fig. 3C]). It is
therefore more likely that the effects observed upon transfer
of enhancing regions from SI genes to NSI genes result from
the "activation" of cryptic SIRs present in the NSI back-
ground through the functional interactions postulated here.
The SIR-containing HC fragment codes for 107 amino
acids and encompasses the hypervariable region V3, which
suggests that the V3 loop region is a major determinant for
syncytium formation for the envelope genes studied here.
The SI clone-derived V3 loops (16.1 and 16.2) share a
positively charged amino acid (arginine) at position 25 of the
V3 loop, whereas the NSI clone-derived V3 loops (16.3 and
16.4) both have a negatively charged glutamic acid at this
position. This same phenotype-correlated amino acid varia-
tion has also been found in a large set of V3 loop sequences
(11). The four parental genes, however, also showed consid-
erable amino acid variation just C terminal of the V3 loop
itself. This region, which is present in the small HC frag-
ment, also contains phenotype-associated amino acid varia-
tions, e.g., the SI genes have a positively charged residue
(lysine) at position 351, where the NSI genes have a nega-
tively charged glutamic acid residue (1). Additional experi-
ments to demonstrate exactly which residues on the HC
fragment are responsible for the observed transfer of SI
capacity are needed.
Interestingly, the extremely small SI gene-derived SS
fragment alone is also capable of transferring SI capacity to
an NSI gene product. This SS fragment, coding for only 71
amino acids, encompasses part of the variable region Vl and
the complete variable region V2. The Vl region is identical
for all four parental envelope proteins, and all amino acid
variation of the SS fragment is confined to the V2 region.
Constructs 24XS, 42HC, 32HC, and 42SSCX, all based on
16.2 SI envelope sequences, demonstrate that the V2 region
is also an important determinant in syncytium formation for
the 16.2 envelope. Examination of the amino acid variation
of the V2 region revealed that the SI clone-derived V2
sequences differ from the NSI clone-derived sequences in
charge and predicted secondary structure. The variable
amino acids of the SI V2 sequences are often positively
charged residues, whereas the NSI V2 sequences mostly
carry polar but uncharged residues at these positions which
results in a higher net positive charge for this region in SI
genes (Fig. 4). Computer analysis (Gamier-Robson analysis
[15]) shows that the variation of residues 8 and 17 greatly
affects the predicted secondary structure of the V2 loop. In
contrast to the NSI clone-derived V2 region, the SI clone-
derived sequence of the N-terminal part of the V2 region is
very likely to form a stable a-helix (Fig. 4). The importance
of these V2 loop features in syncytium formation is currently
being tested in site-directed mutagenesis studies. A previous
report describing the mapping of a virus-neutralizing anti-
body to the V2 region also suggested a role for the V2 region
in the infection process (14). Our data support this notion
and point to a direct role for the V2 region in HIV-1
gpl20-gp41-mediated membrane fusion.
Our data suggest that the V2 and V3 regions are mutually
independent in controlling syncytium formation: when de-
rived from 16.1, both regions transfer considerable SI capac-
ity, with that of the V2 region further enhanced by an
enhancing region. Similarly, the same two regions derived
from 16.2 transfer full SI capacity when the proper enhanc-
ing region, which is the same for both, is present. Thus, the
V2 and V3 regions are the primary SIRs that functionally
interact with the enhancing regions identified here. Syncy-
tium formation can apparently be achieved through at least
two different determinants on gpl20, and in the SI envelope
genes studied here, both are functional. For the V3 region,
basic residues at positions 11 or 28 are linked to the SI
phenotype, and all SI isolates so far appear to have this
configuration (11). However, it is not known whether the SI
phenotype of these isolates is mediated solely through the
SI charge
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TABLE 2. SIRs with the corresponding enhancing regions
Syncytium size Protein or fragment causing
SIR induced by enhanced SIR function
SIR
16.1
V2 + + 16.1 gp4l (AX fragment)
V3 +++ ?
16.2
V2 ++/+ 16.2 CA fragment
V3 + +/+ 16.2 CA fragment
V3 region or whether the V2 region also plays a role. It
would be of interest to determine whether a consensus SI
configuration for V2 can be found in order to answer these
questions.
For the context-dependent SIRs identified in this study,
additional sequences are required for transfer of maximal SI
capacity. The transfer of SI capacity by the 16.2 V3 region is
enhanced by simultaneous exchange of at least the CvnI-
AvrII envelope region at the carboxy terminus of gp120
(constructs 24SA and 23SA [Fig. 3C]). To increase transfer
of SI capacity by the V2 region of the same (16.2) SI
envelope, this CvnI-AvrII region is apparently necessary
(constructs 42HC, 42SSCX, and 32HC). This fragment con-
tains the V4-C4-V5 regions on gp120 and part of gp4l.
Interestingly, evidence for physical interaction between the
C4 region and the V3 loop has been described by others (39)
and may well explain the observed functional interaction
between the V3 as an SIR and this enhancing region.
Transfer of SI capacity by the 16.1 V2 region is enhanced
by the AX region of the same SI gene (construct 31SA). This
same AX region from 16.1, but not 16.2, could also transfer
some SI capacity to NSI envelope 16.3, probably through
activation of a cryptic context-dependent SIR on 16.3. For
an overview of the functional interactions between SIRs and
enhancing regions, see Table 2.
Identification of any region as an SIR or an enhancing
region heavily depends on the sequences of all other regions
involved. Probably even the context-independent SIR (V3
region 16.1) functionally interacts with the enhancing regions
identified here, but the exact sequence of the enhancing
region is less restricted than for the other SIRs. Cryptic SIRs
on NSI envelope genes (for instance, 16.3) can be activated
by acquisition of an enhancing region with the proper
sequence, e.g., through recombination. We have previously
demonstrated that recombination does occur in vivo in an
infected individual (18). This result means that regions
involved in syncytium formation do not necessarily have to
coevolve in the same virus to generate an SI variant. Even
recombination between two NSI envelope genes, one con-
taining a cryptic SIR and the other containing an enhancing
region could therefore lead to an SI virus. We are currently
testing this hypothesis. Such mechanisms greatly enhance
the dynamics of the evolution of HIV-1.
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